Astellas Pharma acquired the remaining outstanding shares of immuno-oncology partner Potenza Therapeutics for ~$165M upfront plus up to $240M in contingent milestones (~$405M total). Strengthens Astellas' immuno-oncology pipeline including TIGIT and GITR antibodies.